{"id":123,"date":"2020-05-01T08:10:47","date_gmt":"2020-05-01T12:10:47","guid":{"rendered":"http:\/\/blog.pharmadiversityjobboard.com\/?p=123"},"modified":"2020-05-04T08:09:20","modified_gmt":"2020-05-04T12:09:20","slug":"fda-in-talks-to-approve-antiviral-remdesivir-to-treat-covid-19","status":"publish","type":"post","link":"https:\/\/blog.pharmadiversityjobboard.com\/?p=123","title":{"rendered":"FDA Approves Antiviral Remdesivir to Treat COVID-19"},"content":{"rendered":"\n<p style=\"text-align: justify;\">Gilead Sciences, Inc. <a href=\"https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/5\/gileads-investigational-antiviral-remdesivir-receives-us-food-and-drug-administration-emergency-use-authorization-for-the-treatment-of-covid19\" target=\"new\" rel=\"noopener noreferrer\">announced<\/a> on Friday that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19. The authorization came after their government-funded Phase III SIMPLE trial, which evaluated 5-day and 10-day dosing of the antiviral remdesivir in hospitalized patients with severe cases of COVID-19, showed promising results. The study found that patients who took remdesivir recovered faster than patients who did not, improving recovery time for coronavirus patients from 15 to 11 days.<\/p>\n\n<p style=\"text-align: justify;\">\u201cThis EUA opens the way for us to provide emergency use of remdesivir to more patients with severe symptoms of COVID-19,\u201d said Daniel O\u2019Day, Chairman and Chief Executive Officer of Gilead Sciences, in a statement released on Friday. \u201cWe will continue to work with partners across the globe to increase our supply of remdesivir while advancing our ongoing clinical trials to supplement our understanding of the drug\u2019s profile. We are working to meet the needs of patients, their families and healthcare workers around the world with the greatest sense of urgency and responsibility.\u201d<\/p>\n\n<p style=\"text-align: justify;\">Gilead has since donated their \u201centire supply\u201d of the medication, with O&#8217;Day telling CBS&#8217; \u201cFace the Nation\u201d on Sunday, \u201cWe\u2019ve donated the entire supply that we have within our supply chain and we did that because we acknowledge and recognize the human suffering, the human need here, and want to make sure nothing gets in the way of this getting to patients.\u201d<\/p>\n\n<p style=\"text-align: justify;\">Remdesivir is currently the only authorized treatment of hospitalized patients with severe COVID-19 disease.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The FDA has approved the very first treatment for COVID-19, and the drugmaker has donated their &#8220;entire supply.&#8221;<\/p>\n","protected":false},"author":1,"featured_media":124,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":""},"categories":[4],"tags":[21,22,10,9,11,14,5],"jetpack_featured_media_url":"https:\/\/blog.pharmadiversityjobboard.com\/wp-content\/uploads\/2020\/05\/iStock-538618761.jpg","_links":{"self":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/123"}],"collection":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=123"}],"version-history":[{"count":3,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/123\/revisions"}],"predecessor-version":[{"id":129,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/posts\/123\/revisions\/129"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=\/wp\/v2\/media\/124"}],"wp:attachment":[{"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.pharmadiversityjobboard.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}